July 1st 2020, 10:42pm
Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.
July 1st 2020, 9:29pm
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.
July 1st 2020, 8:57pm
The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
July 1st 2020, 6:24pm
The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.
July 1st 2020, 6:21pm
Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.
July 1st 2020, 5:24pm
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.
July 1st 2020, 4:30pm
Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.
June 29th 2020, 8:11pm
The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.
June 25th 2020, 3:10pm
Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.
June 22nd 2020, 10:00pm
Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.
